WO2001090758A3 - Diagnosis of alzheimer's disease ldl receptor protein-1 - Google Patents

Diagnosis of alzheimer's disease ldl receptor protein-1 Download PDF

Info

Publication number
WO2001090758A3
WO2001090758A3 PCT/US2001/016561 US0116561W WO0190758A3 WO 2001090758 A3 WO2001090758 A3 WO 2001090758A3 US 0116561 W US0116561 W US 0116561W WO 0190758 A3 WO0190758 A3 WO 0190758A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
brain
diagnosis
receptor protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/016561
Other languages
French (fr)
Other versions
WO2001090758A2 (en
Inventor
Berislav V Zlokovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to US10/296,168 priority Critical patent/US7695903B2/en
Priority to AU2001264801A priority patent/AU2001264801A1/en
Priority to EP01939264A priority patent/EP1290451B1/en
Priority to DE60115638T priority patent/DE60115638T2/en
Priority to AT01939264T priority patent/ATE312354T1/en
Priority to JP2001586471A priority patent/JP4851676B2/en
Priority to CA002408566A priority patent/CA2408566A1/en
Publication of WO2001090758A2 publication Critical patent/WO2001090758A2/en
Publication of WO2001090758A3 publication Critical patent/WO2001090758A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

Brain endothelial low-density lipoprotein receptor related protein-1 (LRP-1) mediates vascular clearance of Alzheimer's amyloid-β peptide (Aβ) from the brain. Transport of Aβ occurs across the blood-brain barrier (BBB) to the systemic circulation, but the brain endothelium is compromised in Alzheimer's disease. The invention is used to diagnose the disease in symptomatic and asymptomatic individuals, to identify those at risk for disease or already affected thereby, to determine the stage of disease or its progression, to intervene earlier in or alter the disease's natural history, to provide a target for therapeutic or prophylactic treatments, to screen drugs or compare medical regimens, to determine the effectiveness of a drug or medical regimen, or any combination thereof.
PCT/US2001/016561 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1 Ceased WO2001090758A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/296,168 US7695903B2 (en) 2000-05-23 2001-05-23 Low-density lipoprotein receptor related protein-1 (LRP-1)in clearance of alzheimer's amyloid-beta peptide from the central nervous system
AU2001264801A AU2001264801A1 (en) 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1
EP01939264A EP1290451B1 (en) 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease using ldl receptor protein-1
DE60115638T DE60115638T2 (en) 2000-05-23 2001-05-23 DIAGNOSIS OF ALZHEIMER'S DISEASE USING LDL RECEPTOR PROTEIN-1
AT01939264T ATE312354T1 (en) 2000-05-23 2001-05-23 DIAGNOSIS OF ALZHEIMER'S DISEASE USING LDL RECEPTOR PROTEIN-1
JP2001586471A JP4851676B2 (en) 2000-05-23 2001-05-23 Role of LDL receptor protein 1 (LRP-1) in Alzheimer's disease
CA002408566A CA2408566A1 (en) 2000-05-23 2001-05-23 Role of ldl receptor protein-1 (lrp-1) in alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20642800P 2000-05-23 2000-05-23
US60/206,428 2000-05-23
US24626800P 2000-11-06 2000-11-06
US60/246,268 2000-11-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10296168 A-371-Of-International 2001-05-23
US10/794,425 Continuation-In-Part US20040259159A1 (en) 2000-05-23 2004-03-08 Role of LDL receptor protein-1 (LRP-1) in Alzheimer's disease

Publications (2)

Publication Number Publication Date
WO2001090758A2 WO2001090758A2 (en) 2001-11-29
WO2001090758A3 true WO2001090758A3 (en) 2002-08-29

Family

ID=26901346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016561 Ceased WO2001090758A2 (en) 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1

Country Status (8)

Country Link
US (2) US7695903B2 (en)
EP (1) EP1290451B1 (en)
JP (1) JP4851676B2 (en)
AT (1) ATE312354T1 (en)
AU (1) AU2001264801A1 (en)
CA (1) CA2408566A1 (en)
DE (1) DE60115638T2 (en)
WO (1) WO2001090758A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037499B1 (en) 1996-11-14 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Adjuvant for transcutaneous immunization
US7378097B2 (en) 1996-11-14 2008-05-27 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312354T1 (en) * 2000-05-23 2005-12-15 Univ Southern California DIAGNOSIS OF ALZHEIMER'S DISEASE USING LDL RECEPTOR PROTEIN-1
DK1372708T3 (en) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine for transcutaneous immunization against travel animals
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
US7608586B2 (en) * 2003-06-11 2009-10-27 The University Of Rochester Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide
ES2332846B1 (en) 2007-10-26 2010-07-08 Grifols, S.A. USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS.
US8946165B2 (en) * 2008-09-29 2015-02-03 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
CA2777752A1 (en) * 2009-10-17 2011-04-21 Zz Alztech L.L.C. Mutant low-density lipoprotein receptor related protein with increased binding to alzheimer amyloid-beta peptide
US20220113320A1 (en) * 2019-01-10 2022-04-14 Fundación Biomédica Galicia Sur (Fbgs) In vitro method for the diagnosis or prognosis of neurodegenerative disorders
CN110192859B (en) * 2019-05-05 2020-05-19 兰月 A magnetic resonance method to measure the clearance efficiency of human brain lymphoid pathways
KR102549828B1 (en) * 2021-03-22 2023-07-04 경희대학교 산학협력단 Blood Brain Barrier-On-a-Chip

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004794A1 (en) * 1995-07-27 1997-02-13 The American National Red Cross Modulators of expression and function of lrp in alzheimer's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5766856A (en) 1984-03-19 1998-06-16 The Picower Institute For Medical Research Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
US5202424A (en) 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4900747A (en) 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
DE69321893T2 (en) * 1992-07-22 1999-05-12 Mclean Hospital Corp Procedure for the detection of Alzheimer's disease
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5962245A (en) 1995-04-05 1999-10-05 The Picower Institute For Medical Research Methods for detecting the presence of advanced glycosylation endproducts
US6156311A (en) 1995-07-27 2000-12-05 The American National Red Cross Modulators of expression and function of LRP in alzheimer's disease
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6472140B1 (en) 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
US6413512B1 (en) 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
ATE312354T1 (en) * 2000-05-23 2005-12-15 Univ Southern California DIAGNOSIS OF ALZHEIMER'S DISEASE USING LDL RECEPTOR PROTEIN-1
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
EP1532258A4 (en) * 2002-06-11 2006-11-02 Socratech L L C TREATMENT OF VASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004794A1 (en) * 1995-07-27 1997-02-13 The American National Red Cross Modulators of expression and function of lrp in alzheimer's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JORDAN J ET AL: "ISOFORM-SPECIFIC EFFECT OF APOLIPOPROTEIN E ON CELL SURVIVAL AND BETA-AMYLOID-INDUCED TOXICITY IN RAT HIPPOCAMPAL PYRAMIDAL NEURONAL CULTURES", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 18, no. 1, 1 January 1998 (1998-01-01), pages 195 - 204, XP002930147, ISSN: 0270-6474 *
NARITA M ET AL: "ALPHA2-MACROGLOBULIN COMPLEXES WITH AND MEDIATES THE ENDOCYTOSIS OF BETA-AMYLOID PEPTIDE VIA CELL SURFACE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 69, no. 5, 1997, pages 1904 - 1911, XP000921049, ISSN: 0022-3042 *
QIU ZHIHUA ET AL: "alpha2-Macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons.", JOURNAL OF NEUROCHEMISTRY, vol. 73, no. 4, October 1999 (1999-10-01), pages 1393 - 1398, XP008003745, ISSN: 0022-3042 *
SHIBATA MASAYOSHI ET AL: "Clearance of Alzheimer's amyloid-beta1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.", JOURNAL OF CLINICAL INVESTIGATION, vol. 106, no. 12, December 2000 (2000-12-01), pages 1489 - 1499, XP001077700, ISSN: 0021-9738 *
ZLOKOVIC B V ET AL: "Role of low-density lipoprotein receptor related protein-1 in vascular clearance of amyloidbeta1-40 peptide from brain.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 275.18, XP001077059, ISSN: 0190-5295 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037499B1 (en) 1996-11-14 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Adjuvant for transcutaneous immunization
US7378097B2 (en) 1996-11-14 2008-05-27 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant

Also Published As

Publication number Publication date
JP4851676B2 (en) 2012-01-11
CA2408566A1 (en) 2001-11-29
DE60115638D1 (en) 2006-01-12
US20040259159A1 (en) 2004-12-23
DE60115638T2 (en) 2006-08-17
JP2004510957A (en) 2004-04-08
WO2001090758A2 (en) 2001-11-29
US7695903B2 (en) 2010-04-13
EP1290451B1 (en) 2005-12-07
AU2001264801A1 (en) 2001-12-03
US20050239062A1 (en) 2005-10-27
EP1290451A2 (en) 2003-03-12
ATE312354T1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2001090758A3 (en) Diagnosis of alzheimer's disease ldl receptor protein-1
Mourad et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
CA2468771A1 (en) Pharmaceutical composition for use in ophthalmology and rhinology
EP1994937A3 (en) Prevention and treatment of amyloidogenic disease
HU229986B1 (en) Prevention and treatment of amyloidogenic disease
ID30171A (en) FORMOTEROL COMBINATIONS AND FUROAT MOMETASONS FOR ASMA
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
MA29273B1 (en) SYNERGISTIC COMBINATION OF XOLAIR / OMALIZUMAB / E25 AND AN IMMUNOSUPPRESSEUR AGENT
SE9704644D0 (en) New use
Adler et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Cheung et al. Assessing duration of antihypertensive effects with whole-day blood pressure monitoring
BRPI0404050A (en) Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment.
Djavan α1-Adenoceptor Antagonists for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): State of the Art
Ferris Switching previous therapies for Alzheimer's disease to galantamine
Kocsis et al. Pharmacotherapy for ‘pure’dysthymia: setraline vs. imipramine and placebo
Hansson et al. VIEWPOINT The Antiatherosclerotic Effect of Calcium Antagonists in Man—What did MIDAS Actually Show?
Glasser et al. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension
Forsythe HIV/AIDS and tourism
DE50005282D1 (en) MEDICINE AND MATCHED COMBINATION OF MEDICINES
Chobanian Current Use of Diuretics in the Management of Hypertension
Mahavadi Autophagy in Amiodarone induced Lung Fibrosis: A Close Look
Shashkov et al. Pharmacological prophylaxis of vestibulo-autonomous syndrome (motion sickness) in model investigations
Nixon Hodgkin's disease involving the skin
Richardson Can physicians effect persistent control of blood pressure?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2408566

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001939264

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001939264

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296168

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2001939264

Country of ref document: EP